Participants sought: Effectiveness of ondansetron to reduce positive, negative and cognitive symptoms in schizophrenia

Molecule of interest affects neurotrans-
mitter serotonin. Image: Wikipedia

Monash Alfred Psychiatry Research Centre (MAPrc) is seeking volunteers diagnosed with schizophrenia to participate in a new study looking at the effectiveness of Ondansetron in reducing positive, negative and cognitive symptoms of schizophrenia.

What does our research involve?

• 12 week trial consisting of 5 study visits
• Two participant groups – patients taking clozapine and patients taking other atypical antipsychotic
• Participants in each group will be randomised to receive either ondansetron or placebo.

Participation criteria

• Aged 18-65
• Current diagnosis of schizophrenia, schizoaffective or schizophreniform disorder
• Current treatment with a stable and standard dose of an atypical antipsychotic medication, oral or intramuscular (minimum of eight weeks) - includes clozapine
• Ability to provide informed consent

Contact:

Dr Annette Webb

• Ph: +61 3 90766590
• email: annette.webb@monash.edu

web: http://www.maprc.org.au/